[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:acute-biphenotypic-leukemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":78,"states":79},"Acute Biphenotypic Leukemia",11,8,[8,16,22,29,35,41,47,53,59,66,73],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05848687","TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:24.970704Z","2026-05-05T02:43:29.336397Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04047641","Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[12],"2026-08-26T02:18:20.384845Z","2026-05-05T02:43:27.571859Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT02115295","Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia",[26],"Phase 2","2026-08-26T02:19:11.399072Z","2026-05-05T02:35:31.645116Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05794880","MCW Alpha\u002FBeta T-Cell and B-Cell Depletion With Targeted ATG Dosing",[],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.363482Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[26],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT03779854","Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant",[26],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:27.279311Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT04065399","A Study of Revumenib in R\u002FR Leukemias Including Those With an MLL\u002FKMT2A Gene Rearrangement or NPM1 Mutation",[12],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:27.111185Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT03683433","Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation",[26],"2026-08-26T02:15:43.339060Z","2026-04-29T02:57:57.075222Z",{"nct_id":60,"title":61,"phases":62,"status":63,"updated_at":64,"content_modified":65},"NCT07572929","A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant",[26],"NOT_YET_RECRUITING","2026-08-26T02:16:11.347936Z","2026-05-13T02:55:06.778094Z",{"nct_id":67,"title":68,"phases":69,"status":70,"updated_at":71,"content_modified":72},"NCT05589896","A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:35:37.456806Z","2026-05-05T02:43:29.711460Z",{"nct_id":74,"title":75,"phases":76,"status":70,"updated_at":71,"content_modified":77},"NCT03739502","A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant",[26],"2026-05-05T02:43:28.822840Z",[],[80,84,88,91,95,98,101,104],{"state":81,"count":82,"slug":83},"Texas",6,"texas",{"state":85,"count":86,"slug":87},"California",4,"california",{"state":89,"count":86,"slug":90},"Oregon","oregon",{"state":92,"count":93,"slug":94},"Florida",3,"florida",{"state":96,"count":93,"slug":97},"Georgia","georgia",{"state":99,"count":93,"slug":100},"New York","new-york",{"state":102,"count":93,"slug":103},"Pennsylvania","pennsylvania",{"state":105,"count":93,"slug":106},"Utah","utah"]